Short Interest in NewGenIvf Group Limited (NASDAQ:NIVF) Rises By 1,821.6%

NewGenIvf Group Limited (NASDAQ:NIVF) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 171,641 shares, a growth of 1,821.6% from the July 30th total of 8,932 shares. Based on an average trading volume of 608,157 shares, the short-interest ratio is presently 0.3 days. Approximately 4.3% of the shares of the company are short sold.

NewGenIvf Group Stock Down 13.5%

Shares of NIVF opened at $0.47 on Thursday. The business’s 50-day moving average price is $1.12 and its 200-day moving average price is $4.08. NewGenIvf Group has a twelve month low of $0.45 and a twelve month high of $513.00. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16.

NewGenIvf Group’s stock is set to reverse split before the market opens on Tuesday, September 1st. The 1-3 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on NIVF shares. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings restated a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.